BCAX Bicara Therapeutics Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 11, 2026
$17.63
· of 52w range
· above low
· to high
$13.7052w low
$30.9952w high
Market Cap (MRQ)
$1.16B
P/E
-8.1
EPS
$-2.52
your badges
52W Range
$14–$31
Analyst Rating
BUY
Price Target
$35
P/E
-8.1
ROE
-33.0%
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
BCAX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$17.63
Market Cap (MRQ)
$1.16B
P/E
-8.1
EPS
$-2.52
ROE
-33.0%
52W Range
$14–$31
BCAX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
EPS$-2.522023-12-31 → 2025-12-31
Free Cash Flow$-107M2024-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | BCAX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -8.1 | · | · | · | |
| P/B (MRQ) | 2.5 | · | 4.2 | Fair value | |
| Price / FCF (TTM) | -8.6 | · | · | · | |
| Price / Cash Flow (TTM) | -8.6 | · | · | · | |
| Price / Tangible Book | 2.9 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | BCAX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -29.3% | · | -37.9% | Top tier | |
| ROE | -33.0% | · | -36.5% | In line | |
| ROIC | -38.8% | · | -87.8% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | BCAX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 11.6 | · | 12.4 | In line | |
| Quick Ratio | 14.3 | · | 8.3 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-14.5%
Next Report
Nov 09, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 11, 2026 | $-0.82 | $-0.85 | 3.2% |
| March 31, 2026 | May 19, 2026 | $-0.93 | $-0.77 | -20.8% |
| Dec. 31, 2025 | $-0.68 | $-0.68 | 0.66% | |
| Sept. 30, 2025 | $-0.67 | $-0.56 | -19.6% | |
| June 30, 2025 | $-0.50 | $-0.58 | 13.8% | |
| March 31, 2025 | $-0.68 | $-0.42 | -60.7% | |
| Dec. 31, 2024 | $-0.39 | $-0.33 | -18.2% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| R&D Expense | · | $64M | $31M | |
| SG&A Expense | $31M | $19M | $9M | |
| Operating Expenses | $156M | $82M | $40M | |
| Operating Income | $-156M | $-82M | $-40M | |
| Interest Income | $18M | $15M | $1M | |
| Other Non-op | $18M | $15M | $-12M | |
| Pretax Income | $-138M | $-68M | $-52M | |
| Income Tax | $217.0K | $187.0K | $5.0K | |
| Net Income | $-138M | $-68M | $-52M | |
| EPS (Basic) | $-2.52 | $-4.05 | $-89.61 | |
| EPS (Diluted) | $-2.52 | $-4.05 | $-89.61 | |
| Shares (Basic) | 54,676,896,000 | 16,805,524,000 | 580,109,000 | |
| Shares (Diluted) | 54,676,896,000 | 16,805,524,000 | 580,109,000 | |
| EBITDA | $-156M | $-82M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $97M | $490M | $230M | |
| Short-term Investments | $318M | $0 | · | |
| Prepaid Expense | $7M | $13M | $633.0K | |
| Current Assets | $422M | $503M | $231M | |
| PP&E (Net) | $330.0K | $155.0K | $202.0K | |
| Other Non-current Assets | $7M | $7M | $2M | |
| Total Assets | $431M | $510M | $234M | |
| Accrued Liabilities | · | $13M | $8M | |
| Current Liabilities | $29M | $18M | $15M | |
| Capital Leases | $593.0K | $131.0K | $372.0K | |
| Other Non-current Liabilities | · | $0 | $17.0K | |
| Total Liabilities | $30M | $18M | $15M | |
| Common Stock | $7.0K | $7.0K | $2.0K | |
| Paid-in Capital | $760M | $713M | $4M | |
| Retained Earnings | $-359M | $-221M | $-153M | |
| AOCI | $243.0K | $0 | · | |
| Stockholders' Equity | $401M | $492M | $-149M | |
| Liabilities + Equity | $431M | $510M | $234M | |
| Shares Outstanding | 56,600,724 | 54,440,013 | 640,386 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Stock-based Comp | $15M | $7M | $2M | |
| Deferred Tax | $0 | $0 | $0 | |
| Operating Cash Flow | $-107M | $-75M | $-46M | |
| CapEx | $280.0K | $71.0K | $586.0K | |
| Investing Cash Flow | $-318M | $-9.0K | $-586.0K | |
| Stock Issued | $29M | $332M | $0 | |
| Net Stock Activity | $29M | $332M | · | |
| Financing Cash Flow | $32M | $334M | $272M | |
| Net Change in Cash | $-393M | $259M | $226M | |
| Free Cash Flow | $-107M | $-75M | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| ROA | -29.3% | -18.3% | · | |
| ROE | -33.0% | -13.6% | · | |
| ROIC | -38.8% | -16.8% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Current Ratio | 14.6 | 27.9 | · | |
| Quick Ratio | 14.3 | 27.2 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Book Value / Share | $7.09 | $9.04 | · | |
| Cash Flow / Share | $-0.00 | $-0.00 | · | |
| Cash / Share | $1.71 | $9.00 | · | |
| EPS (TTM) | $-2.52 | $-4.05 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net Income TTM | $-138M | $-68M | · | |
| Market Cap | $953M | $948M | · | |
| P/E | -6.7 | -4.3 | · | |
| P/B | 2.4 | 1.9 | · | |
| P / Tangible Book | 2.4 | 1.9 | · | |
| P / Cash Flow | -8.9 | -12.7 | · | |
| P / FCF | -8.9 | -12.7 | · | |
| Earnings Yield | -15.0% | -23.2% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | · | · | · | $33M | $25M | $34M | · | $16M | $16M | $12M | $10M | $7M | |
| SG&A Expense | $14M | $13M | $8M | $8M | $7M | $7M | $7M | $5M | $4M | $3M | $3M | $3M | |
| Operating Expenses | $60M | $60M | $41M | $41M | $32M | $42M | $27M | $21M | $20M | $15M | $14M | $10M | |
| Operating Income | $-60M | $-60M | $-41M | $-41M | $-32M | $-42M | $-27M | $-21M | $-20M | $-15M | $-14M | $-10M | |
| Interest Income | $5M | $4M | $4M | $4M | $5M | $5M | $6M | $3M | $3M | $3M | $1M | $13.0K | |
| Other Non-op | $5M | $4M | $4M | $4M | $5M | $5M | $6M | $3M | $3M | $3M | $1M | $-13M | |
| Pretax Income | $-55M | $-56M | $-37M | $-36M | $-27M | $-37M | $-21M | $-17M | $-17M | $-13M | $-12M | $-23M | |
| Income Tax | $61.0K | $52.0K | $53.0K | $40.0K | $52.0K | $72.0K | $186.0K | $0 | $0 | $1.0K | $5.0K | $0 | |
| Net Income | $-55M | $-56M | $-37M | $-36M | $-27M | $-37M | $-21M | $-17M | $-17M | $-13M | $-12M | $-23M | |
| EPS (Basic) | $-0.82 | $-0.93 | $-0.67 | $-0.67 | $-0.50 | $-0.68 | $35.50 | $-1.60 | $-19.01 | $-18.94 | $-19.43 | $-38.23 | |
| EPS (Diluted) | $-0.82 | $-0.93 | $-0.67 | $-0.67 | $-0.50 | $-0.68 | $35.50 | $-1.60 | $-19.01 | $-18.94 | $-19.43 | $-38.23 | |
| Shares (Basic) | 67,925,963 | 60,717,041 | · | 54,563,864 | 54,539,230 | 54,456,515 | · | 10,901,138 | 896,744 | 660,288 | · | 597,586 | |
| Shares (Diluted) | 67,925,963 | 60,717,041 | · | 54,563,864 | 54,539,230 | 54,456,515 | · | 10,901,138 | 896,744 | 660,288 | · | 597,586 | |
| EBITDA | $-60M | $-60M | · | $-41M | $-32M | $-42M | · | $-21M | · | · | · | · |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $97M | $323M | $97M | $172M | $437M | $462M | $490M | $521M | · | · | $230M | · | |
| Short-term Investments | $401M | $216M | $318M | $118M | · | · | $0 | · | · | · | · | · | |
| Prepaid Expense | $7M | $5M | $7M | $7M | $8M | $9M | $13M | $756.0K | · | · | $633.0K | · | |
| Current Assets | $504M | $545M | $422M | $297M | $444M | $471M | $503M | $522M | · | · | $231M | · | |
| PP&E (Net) | $362.0K | $346.0K | $330.0K | $135.0K | $117.0K | $136.0K | $155.0K | $130.0K | · | · | $202.0K | · | |
| Other Non-current Assets | $7M | $7M | $7M | $8M | $7M | $7M | $7M | $2M | · | · | $2M | · | |
| Total Assets | $512M | $554M | $431M | $425M | $454M | $478M | $510M | $524M | · | · | $234M | · | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | $8M | · | |
| Current Liabilities | $43M | $39M | $29M | $21M | $17M | $19M | $18M | $14M | · | · | $15M | · | |
| Capital Leases | $0 | $301.0K | $593.0K | $880.0K | $1M | $0 | $131.0K | $137.0K | · | · | $372.0K | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $0 | · | · | $17.0K | · | |
| Total Liabilities | $43M | $40M | $30M | $22M | $18M | $19M | $18M | $15M | · | · | $15M | · | |
| Common Stock | $8.0K | $8.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | · | · | $2.0K | · | |
| Paid-in Capital | $940M | $929M | $760M | $724M | $720M | $717M | $713M | $710M | · | · | $4M | · | |
| Retained Earnings | $-471M | $-415M | $-359M | $-322M | $-285M | $-258M | $-221M | $-200M | · | · | $-153M | · | |
| AOCI | $-567.0K | $-243.0K | $243.0K | $-136.0K | · | · | $0 | · | · | · | · | · | |
| Stockholders' Equity | $469M | $514M | $401M | $403M | $435M | $459M | $492M | $510M | · | · | $-149M | · | |
| Liabilities + Equity | $512M | $554M | $431M | $425M | $454M | $478M | $510M | $524M | · | · | $234M | · | |
| Shares Outstanding | 65,931,128 | 65,547,037 | 56,600,724 | 54,612,477 | 54,556,078 | 54,528,975 | 54,440,013 | 54,409,708 | · | · | 640,386 | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $8M | $6M | $4M | $4M | $3M | $3M | $3M | $2M | $1M | $1M | $765.0K | · | |
| Operating Cash Flow | $-44M | $-38M | $-24M | $-29M | $-26M | $-28M | $-30M | $-17M | $-13M | $-15M | $-8M | · | |
| CapEx | $60.0K | $60.0K | $238.0K | $42.0K | $0 | $0 | $40.0K | $8.0K | $19.0K | $4.0K | $436.0K | · | |
| Investing Cash Flow | $-185M | $101M | $-82M | $-236M | $0 | $0 | $-40.0K | $-8.0K | $-19.0K | $58.0K | $-436.0K | · | |
| Stock Issued | $0 | $162M | $29M | $0 | $0 | $0 | $-1M | · | · | · | $0 | · | |
| Net Stock Activity | · | $162M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $2M | $163M | $31M | $436.0K | $135.0K | $460.0K | $-975.0K | $334M | $734.0K | $137.0K | $195M | · | |
| Net Change in Cash | $-227M | $227M | $-75M | $-265M | $-25M | $-28M | $-31M | $317M | $-12M | $-14M | $186M | · | |
| Free Cash Flow | · | $-38M | · | · | · | $-28M | · | · | · | · | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -11.5% | -10.9% | · | -7.7% | -12.1% | -15.4% | · | -6.7% | · | · | · | · | |
| ROE | -12.3% | -11.6% | · | -8.0% | -12.6% | -16.1% | · | -6.9% | · | · | · | · | |
| ROIC | -12.8% | -11.7% | · | -10.1% | -7.4% | -9.1% | · | -4.0% | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.6 | 13.9 | · | 14.1 | 25.8 | 24.6 | · | 36.0 | · | · | · | · | |
| Quick Ratio | 11.4 | 13.7 | · | 13.8 | 25.3 | 24.2 | · | 36.0 | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.11 | $7.84 | · | $7.38 | $7.98 | $8.42 | · | $9.37 | · | · | · | · | |
| Cash Flow / Share | · | $-0.62 | · | · | · | $-0.52 | · | · | · | · | · | · | |
| Cash / Share | $1.47 | $4.93 | · | $3.14 | $8.00 | $8.47 | · | $9.57 | · | · | · | · | |
| EPS (TTM) | $-3.09 | $-2.77 | · | $33.65 | $32.72 | $14.21 | · | $-58.98 | $-95.61 | · | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-185M | $-157M | · | $-122M | $-103M | $-92M | · | $-59M | $-65M | $-57M | · | · | |
| Market Cap | $1.96B | $1.30B | · | $862M | $507M | $711M | · | $1.39B | · | · | · | · | |
| P/E | -9.6 | -7.2 | · | 0.5 | 0.3 | 0.9 | · | -0.4 | · | · | · | · | |
| P/B | 4.2 | 2.5 | · | 2.1 | 1.2 | 1.5 | · | 2.7 | · | · | · | · | |
| P / Tangible Book | 4.2 | 2.5 | · | 2.1 | 1.2 | 1.5 | · | 2.7 | · | · | · | · | |
| P / Cash Flow | · | -34.8 | · | · | · | -25.3 | · | · | · | · | · | · | |
| Earnings Yield | -10.4% | -13.9% | · | 213.1% | 352.2% | 109.1% | · | -231.6% | · | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net Income | $-138M | $-68M | $-52M |
| Diluted EPS | $-2.52 | $-4.05 | $-89.61 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Current Ratio | 14.6 | 27.9 | · |
| Quick Ratio | 14.3 | 27.2 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | $-107M | $-75M | · |
Institutional owners (13F) 183 filers · $1.8B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
183
Value held
$1.8B
New positions
41
Exited positions
9
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 41 (+8 vs prior Q) | 9 (-11 vs prior Q) | 67 (+10 vs prior Q) | 42 (+2 vs prior Q) | -2.2M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $215,430,432 | 7,255,993 | 11.71% | Shares |
| Siren, L.L.C. | $166,352,179 | 5,602,970 | 9.04% | Shares |
| Vestal Point Capital, LP | $155,872,500 | 5,250,000 | 8.47% | Shares |
| Deep Track Capital, LP | $121,729,000 | 4,100,000 | 6.62% | Shares |
| BlackRock, Inc. | $114,249,784 | 3,848,090 | 6.21% | Shares |
| RED TREE MANAGEMENT, LLC | $93,924,820 | 3,163,517 | 5.11% | Shares |
| TPG GP A, LLC | $89,379,518 | 3,010,425 | 4.86% | Shares |
| JANUS HENDERSON GROUP PLC | $66,350,262 | 3,339,218 | 3.61% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $65,812,012 | 2,216,639 | 3.58% | Shares |
| STATE STREET CORP | $60,832,435 | 2,048,920 | 3.31% | Shares |
| FRANKLIN RESOURCES INC | $57,951,672 | 1,951,892 | 3.15% | Shares |
| FMR LLC | $56,205,248 | 1,893,070 | 3.05% | Shares |
| Omega Fund Management, LLC | $54,099,634 | 1,822,150 | 2.94% | Shares |
| VANGUARD GROUP INC | $36,792,904 | 2,186,150 | 2.00% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $34,525,388 | 1,162,635 | 1.88% | Shares |
| JPMORGAN CHASE & CO | $29,808,414 | 1,015,965 | 1.62% | Shares |
| Jones Hill Capital LP | $26,501,917 | 892,621 | 1.44% | Shares |
| ACORN CAPITAL ADVISORS, LLC | $19,102,000 | 643,381 | 1.04% | Shares |
| Aisling Capital Management LP | $16,891,205 | 568,919 | 0.92% | Shares |
| Palo Alto Investors LP | $16,341,614 | 550,408 | 0.89% | Shares |
| Rock Springs Capital Management LP | $15,892,641 | 535,286 | 0.86% | Shares |
| GOLDMAN SACHS GROUP INC | $15,455,635 | 520,567 | 0.84% | Shares |
| D. E. Shaw & Co., Inc. | $14,791,350 | 498,193 | 0.80% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $13,707,173 | 461,724 | 0.75% | Shares |
| NAN FUNG TRINITY (HK) LTD | $12,703,906 | 427,885 | 0.69% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12,437,497 | 418,912 | 0.68% | Shares |
| NORTHERN TRUST CORP | $11,767,424 | 396,343 | 0.64% | Shares |
| Candriam S.C.A. | $11,074,986 | 373,380 | 0.60% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $10,851,131 | 365,481 | 0.59% | Shares |
| Walleye Capital LLC | $10,487,280 | 353,226 | 0.57% | Shares |
| BANK OF AMERICA CORP /DE/ | $10,477,720 | 352,904 | 0.57% | Shares |
| Ensign Peak Advisors, Inc | $10,160,245 | 342,211 | 0.55% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $9,314,911 | 313,739 | 0.51% | Shares |
| Clearbridge Investments, LLC | $8,603,707 | 289,785 | 0.47% | Shares |
| AMERIPRISE FINANCIAL INC | $8,573,036 | 288,749 | 0.47% | Shares |
| DAFNA Capital Management LLC | $8,460,314 | 284,955 | 0.46% | Shares |
| MORGAN STANLEY | $8,428,517 | 283,884 | 0.46% | Shares |
| MILLENNIUM MANAGEMENT LLC | $7,786,321 | 262,254 | 0.42% | Shares |
| TD Asset Management Inc | $7,752,593 | 261,118 | 0.42% | Shares |
| ALGERT GLOBAL LLC | $6,924,658 | 233,232 | 0.38% | Shares |
| Woodline Partners LP | $6,908,566 | 232,690 | 0.38% | Shares |
| SEB Asset Management AB | $6,892,698 | 232,156 | 0.37% | Shares |
| CITADEL ADVISORS LLC | $6,268,806 | 211,142 | 0.34% | Shares |
| ORBIMED ADVISORS LLC | $5,673,759 | 191,100 | 0.31% | Shares |
| Atle Fund Management AB | $4,324,556 | 145,657 | 0.24% | Shares |
| DEUTSCHE BANK AG\ | $4,275,657 | 144,010 | 0.23% | Shares |
| Bank of New York Mellon Corp | $3,582,573 | 120,666 | 0.19% | Shares |
| Napean Trading & Investment Co (Singapore) PTE Ltd | $3,378,128 | 113,780 | 0.18% | Shares |
| Hudson Bay Capital Management LP | $3,117,450 | 105,000 | 0.17% | Shares |
| Jump Financial, LLC | $2,977,907 | 100,300 | 0.16% | Shares |
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, RA Capital Healthcare Fund, L.P. ×2 filings | March 2, 2026 | 11.50% | Amendment | · | SEC |
| TPG GP A, LLC, David Bonderman, James G. Coulter, Jon Winkelried | Sept. 18, 2024 | · | Initial filing | Capital structure | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 18 insiders · 7 officers · 11 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Ryan Cohlhepp | President, COO & Interim CEO | Sept. 8, 2026 M | 181,641 | 0 | 29 | $-4,597,007 |
| Claire Mazumdar | Chief Executive Officer | Aug. 10, 2026 M | 362,152 | 0 | 17 | $-4,057,326 |
| Jennifer Larson | Chief Financial Officer | Aug. 12, 2026 A | · | 0 | 0 | $0 |
| Ivan Hyep | Chief Financial Officer | Aug. 10, 2026 M | 129,855 | 0 | 17 | $-3,241,989 |
| William Schelman | Chief Medical Officer | May 8, 2026 A | · | 0 | 0 | $0 |
| David Raben | Chief Medical Officer | April 27, 2026 M | 55,286 | 0 | 8 | $-1,146,626 |
| Lara Meisner | Chief Legal Officer | Feb. 2, 2026 A | 0 | 0 | 0 | $0 |
| Jeremy Bender | Director | July 28, 2026 A | · | 0 | 0 | $0 |
| Christy J. Oliger | Director | July 28, 2026 A | · | 0 | 0 | $0 |
| Kiran Mazumdar-Shaw | Director | June 9, 2026 A | 432,736 | 0 | 0 | $0 |
| Scott M. Robertson | Director | June 9, 2026 A | · | 0 | 0 | $0 |
| Jake Simson | Director | June 9, 2026 A | · | 0 | 0 | $0 |
| Kate Haviland | Director | June 9, 2026 A | · | 0 | 0 | $0 |
| Christopher Bowden | Director | June 9, 2026 A | · | 0 | 0 | $0 |
| Michael Powell | Director | June 9, 2026 A | · | 0 | 0 | $0 |
| Nils Lonberg | Director | June 9, 2025 A | · | 0 | 0 | $0 |
| FIL Ltd | · | Sept. 16, 2024 C | 1,013,853 | 0 | 0 | $0 |
| FMR LLC | · | Sept. 16, 2024 C | 1,115,333 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 28 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.84% | 14,331 NS | July 31, 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0.44% | 1,484 NS | July 31, 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.20% | 37,261 NS | July 31, 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.08% | 4,676 SH | Oct. 1, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.07% | 41,376 SH | Aug. 19, 2026 | Daily |
| IBB · iShares Trust | 0.06% | 285,883 SH | Sept. 11, 2026 | Daily |
| IWO · iShares Trust | 0.06% | 362,471 SH | Sept. 11, 2026 | Daily |
| PWS · Pacer Funds Trust | 0.06% | 509 NS | July 31, 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.04% | 25,859 SH | Aug. 19, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.04% | 254,350 SH | Aug. 19, 2026 | Daily |
| IWM · iShares Trust | 0.03% | 1,128,793 SH | Sept. 11, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.02% | 138,684 NS | July 31, 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 23,038 SH | Oct. 1, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 14,345 NS | July 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 490,933 SH | Aug. 19, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 4,912 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 88,723 SH | Aug. 19, 2026 | Daily |
| WSML · iShares Trust | 0.01% | 1,706 SH | Sept. 11, 2026 | Daily |
| DCOR · Dimensional ETF Trust | 0.00% | 5,117 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 31,212 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 7,990 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.00% | 67,201 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 9,534 SH | Sept. 3, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.00% | 7,360 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,676,653 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3,692 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 49,578 SH | Sept. 11, 2026 | Daily |
| ISCB · iShares Trust | · | 1,663 SH | Sept. 11, 2026 | Daily |
BCAX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 22 analysts
BUY
Median target
$35.00
+98.5%
7 31.8%
Strong Buy
11 50.0%
Buy
4 18.2%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
13 analysts · 2026-09-30Mean target $34.54 +95.9%
← Below all targets
Current price $17.63
Low$20.00
Mean$34.54
High$45.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| BCAX | $953M | -6.7 | · | · | -33.0% | · |
| REPL | $633M | -2.3 | · | · | -146.2% | · |
| DMRA | · | · | 38.3% | -17981.1% | -167.0% | · |
| TRAX | · | · | · | · | · | · |
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | · |
| VOR | $506M | -0.2 | · | · | 83.4% | · |
| JANX | $833M | -7.5 | -5.5% | -1136.2% | -11.7% | · |
| SVRA | $1.23B | -11.4 | · | · | -73.4% | · |
| AKTS | · | · | · | · | · | · |
| MGTX | $645M | -5.6 | 144.6% | -140.3% | 8062.2% | · |
Latest News Recent headlines mentioning this company
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
Nasdaq · 3 months, 2 weeks ago
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
Nasdaq · 4 months, 2 weeks ago
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?
Yahoo Finance · 6 months ago
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 11, 2026